Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (1874)	1/23/2002 7:41:50 PM
From: Arthur Radley	Read Replies (2) of 2515

You are correct...BMY isn't the first drug company to buy a "pig in a poke". If you go back and look at most of the drugs rejected by the FDA from small biotechs in the past year...most of them had alliances with major companies. GNLB is one that comes to mind. Just in the last week, several failed in Phase III testing...again most had alliances with major companies. Let me ask the question again for the authorities on the subject..."What is the chances that if IMCL goes back and does the required protocol for testing that they might loss the patent on the drug." This is being mentioned as the reason for the lack of adhering to the FDA guidlines.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next